Patient Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (Valsartan/Sacubitril) in Heart Failure (PROVIDE-HF)
PI(s): Robert Mentz, Duke University
Project Summary: This study investigated the change in patient-reported heart failure symptoms (using the Kansas City Cardiomyopathy Questionnaire) following the initiation of sacubitril/valsartan through 12 weeks.
Study Design: Prospective Study
Coordinating Center: Duke University